Hem. Stem Cell Transplant Flashcards
(46 cards)
Types of HSC Transplantation: • Reduced intensity transplant • Less intensive chemotherapy before transplantation of allogeneic stem cells
Non-myeloablative
Types of HSC Transplantation: • Patient’s own hematopoietic stem cells are used • Fewer side effects
Autologous
Graft-Versus-Tumor Effect pathogenesis: T-cell interacts with a dendritic cells and releases 1) –> leads to apoptosis of the tumor cell.
1) granzyme and perforin (CD8+)
Do not get GVHD
Identical twin donors
GVHD primarily 1) mediated, but contributions of other cells types
1) T cell
Higher risk of relapse
Identical twin donors
Recipient T-cell recognizes donor peptides shown in the context of a RECIPIENT MHC and dendritic cell
Indirect Allorecognition:
Autologous transplant mobilized PBPCs (peripheral blood stem/progenitor cells) are superior b/c they have:
(a) accelerated engraftment. (b) Require fewer RBC and platelet transfusions. (c) Results in a shorter hospital stay.
increased serum bilirubin.
Acute GVHD and chronic
Plays a role in ACUTE rejection
Direct Allorecognition:
dry oral mucosa with ulcerations
Chronic GVHD
Mimic features of SLE, sicca syndrome, eosinophilic fasciitis, RA, PBS
Chronic GVHD
most important in initiation of GVHD
HLA-A, B, and DR
HSC Donors: Identical twin donors–> • Do not require 1) • Do not get 2) • Higher risk of relapse
1) post-transplant immunosuppression 2) GVHD 3)
GVHD Unrelated donors with serologic match may have 1) leading to incompatibility
1) different alleles
Traditional source of HSC for allogeneic and autologous transplants
bone Marrow
• Restricted to cells of immune system • HLA-DQ, DR, DP
MHC class II
Preferred donor for allogeneic transplants are:
Matched related donors such as siblings
Use of peripheral precursor cells rather than bone marrow inc. risk of:
chronic GVHD
human platelet antigen 3
minor histocompatibility antigens and difference in host and recipient may cause GVHD
CXCR4 antagonist AMD3100
Mobilizes HSC from marrow into BLOOD
Acute GVHD vs. chronic time period
acute–>First 100 days post-transplant chronic–>After 100 days post-transplant
polymorphism of PECAM (platelet endothelial cellular adhesion molecules)
human platelet antigen 3
Mismatched related donors: Associated with higher risk of 1)
1) GVHD